Considering the safety profile of Bonviva and the large number of patients currently enrolled in clinical and post marketing studies for the product as well as the ongoing post-marketing obligations and the continued reports of adverse events received by the MAH, the safety profile will continue to be monitored closely and updates should be provided regularly to the CHMP through 1-yearly PSURs.